Clinical Trial Update: A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS [Phase 4]

View source ↗

Summary

This clinical trial update reports a Phase 4 study evaluating the efficacy and safety of starting dose 0.25 mg pramipexole (Mirapex) in patients with Restless L…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Pramipexole (Mirapex) (pramipexole)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Restless Legs Syndrome | Phase 4 | Status: COMPLETED